Dr. Janet Chollet

Dr. Janet Chollet has centered her career on clinical medicine, translational research, and the development of therapeutic programs to address persistent unmet needs in women’s health. As a board-certified obstetrician–gynecologist and the Co-Founder and Chief Medical Officer of Procyrn LLC, she guides the advancement of sustained-release biologics and reformulated antivirals. Her work focuses on maternal–fetal health, neuroinflammation, and HPV-related cervical disease, reflecting a steady commitment to responsibly moving scientific concepts toward practical clinical use.

With more than three decades of experience, she has contributed to patient care, academic teaching, and early therapeutic development at leading medical institutions. Her work includes three U.S. patents in drug-delivery systems for women’s health, as well as participation in several preclinical and early-stage programs. These contributions demonstrate her belief that meaningful medical innovation requires disciplined scientific methods, clinical awareness, and clear development pathways.

Her academic foundation began with a Bachelor of Science in Neuroscience, followed by a medical degree and completion of a residency in Obstetrics and Gynecology. The demanding nature of residency training strengthened her long-term interest in improving therapeutic options for women, children, and families. Those formative years shaped her focus on translational medicine and the importance of developing therapies that align with real clinical needs.

After residency, she entered academic clinical practice, balancing patient care with teaching and mentoring responsibilities. These early professional experiences provided insight into how clinical challenges can guide research priorities. She later expanded her work by co-founding a women’s health biotechnology company, where she contributed to drug-delivery innovations that led to several patents and played a role in the company’s eventual merger with a public pharmaceutical organization.

In 2023, she co-founded Procyrn LLC and now directs clinical development, regulatory planning, and translational execution for programs addressing hypertensive disorders of pregnancy, immune-modulating strategies for ALS, and selective treatments for HPV-driven cervical dysplasia. She also evaluates exploratory concepts related to maternal–fetal immune stabilization and its potential influence on early neurodevelopment. Her leadership emphasizes reproducible science, structured milestones, and disciplined decision-making to ensure steady program advancement.

Earlier in her career, she also engaged in creative work, co-writing an episode of a medical television series that received notable recognition. Outside of her professional commitments, she values wellness, family time, travel, and creative expression, while maintaining a growing interest in how emerging technologies may strengthen clinical workflows. Dr. Janet Chollet remains dedicated to advancing therapies that translate scientific understanding into meaningful improvements in patient care.